Literature DB >> 11562117

Postload plasma glucose concentration and 27-year prostate cancer mortality (United States).

S M Gapstur1, P H Gann, L A Colangelo, R Barron-Simpson, P Kopp, A Dyer, K Liu.   

Abstract

OBJECTIVE: Findings from epidemiologic studies on the association between diabetes and prostate cancer risk are inconsistent. However, data from at least three studies suggest that the direction and strength of this association differs according to duration of diabetes. To determine the potential effects of early-stage abnormal glucose metabolism on risk, we assessed the relationship of postload glycemia in the absence of self-reported diabetes with risk of prostate cancer mortality.
METHODS: Data from the Chicago Heart Association Detection Project in Industry were used to examine this relationship. Between 1967 and 1973 some employees of 84 Chicago area organizations underwent a health screening examination. Blood was drawn for measurement of plasma glucose concentration approximately 1 h after a 50-g oral glucose load among 20,433 men. After a mean length of follow-up of 27 years, 176 men died of prostate cancer. Cox regression was used to compute adjusted relative risks (RRs) and 95% confidence intervals (CIs).
RESULTS: After controlling for age, body mass index, heart rate, education, and race, the RRs of prostate cancer mortality for postload plasma glucose levels of 6.7-8.8, 8.9-11, and > or = 11.1 mmol/L compared to < or = 6.6 mmol/L were 1.64, 1.37, and 1.64. respectively (p for trend=0.19). The RR (95% CI) associated with a 2.2 mmol/L (1 standard deviation) higher glucose concentration was 1.1 (0.95-1.2).
CONCLUSIONS: These results provide weak evidence of an association between hyperglycemia and prostate cancer mortality.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11562117     DOI: 10.1023/a:1011279907108

Source DB:  PubMed          Journal:  Cancer Causes Control        ISSN: 0957-5243            Impact factor:   2.506


  16 in total

Review 1.  Body mass index and mortality in prostate cancer patients: a dose-response meta-analysis.

Authors:  S Zhong; X Yan; Y Wu; X Zhang; L Chen; J Tang; J Zhao
Journal:  Prostate Cancer Prostatic Dis       Date:  2016-01-12       Impact factor: 5.554

2.  Serum omentin level in patients with prostate cancer.

Authors:  Ugur Uyeturk; Hasmet Sarıcı; Buket Kın Tekce; Muzaffer Eroglu; Eray Kemahlı; Ummugul Uyeturk; Adnan Gucuk
Journal:  Med Oncol       Date:  2014-03-23       Impact factor: 3.064

3.  Impact of metformin on clinical outcomes among men with prostate cancer: a systematic review and meta-analysis.

Authors:  A D Raval; D Thakker; A Vyas; M Salkini; S Madhavan; U Sambamoorthi
Journal:  Prostate Cancer Prostatic Dis       Date:  2015-02-10       Impact factor: 5.554

4.  Relationship between HbA(1)c and mortality in a Japanese population.

Authors:  S Nakanishi; M Yamada; N Hattori; G Suzuki
Journal:  Diabetologia       Date:  2005-01-14       Impact factor: 10.122

5.  Thiazolidinediones and metformin associated with improved survival of diabetic prostate cancer patients.

Authors:  X-X He; S M Tu; M-H Lee; S-C J Yeung
Journal:  Ann Oncol       Date:  2011-03-17       Impact factor: 32.976

6.  Metformin: A candidate for the treatment of gynecological tumors based on drug repositioning.

Authors:  Haruko Irie; Kouji Banno; Megumi Yanokura; Miho Iida; Masataka Adachi; Kanako Nakamura; Kiyoko Umene; Yuya Nogami; Kenta Masuda; Yusuke Kobayashi; Eiichiro Tominaga; Daisuke Aoki
Journal:  Oncol Lett       Date:  2016-01-07       Impact factor: 2.967

7.  Differential impact of structurally different anti-diabetic drugs on proliferation and chemosensitivity of acute lymphoblastic leukemia cells.

Authors:  Jingxuan Pan; Chun Chen; Yanli Jin; Enrique Fuentes-Mattei; Guermarie Velazquez-Tores; Juliana Maria Benito; Marina Konopleva; Michael Andreeff; Mong-Hong Lee; Sai-Ching Jim Yeung
Journal:  Cell Cycle       Date:  2012-06-15       Impact factor: 4.534

8.  A randomized controlled trial of an intensive insulin regimen in patients with hyperglycemic acute lymphoblastic leukemia.

Authors:  Khanh Vu; Naifa Busaidy; Maria E Cabanillas; Marina Konopleva; Stefan Faderl; Deborah A Thomas; Susan O'Brien; Kristine Broglio; Joe Ensor; Carmen Escalante; Michael Andreeff; Hagop Kantarjian; Victor Lavis; Sai-Ching Jim Yeung
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2012-06-01

9.  Avoiding cancer risk information.

Authors:  Amber S Emanuel; Marc T Kiviniemi; Jennifer L Howell; Jennifer L Hay; Erika A Waters; Heather Orom; James A Shepperd
Journal:  Soc Sci Med       Date:  2015-10-27       Impact factor: 4.634

10.  Diabetes mellitus and prostate cancer risk among older men: population-based case-control study.

Authors:  A L Coker; M Sanderson; W Zheng; M K Fadden
Journal:  Br J Cancer       Date:  2004-06-01       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.